<DOC>
	<DOCNO>NCT00818194</DOCNO>
	<brief_summary>The purpose study compare effect steady state tacrolimus vs. cyclosporine renal pharmacodynamics healthy volunteer .</brief_summary>
	<brief_title>Comparison Extended Release Tacrolimus ( Advagraf ) Cyclosporine A Microemulsion Renal Function Healthy Volunteers</brief_title>
	<detailed_description>This study seek evaluate renal physiological response short-term maintenance level dos CNIs healthy volunteer determine daily perturbation renal physiology exist , confirm , whether differ CNIs thus may contribute different mechanism progression CAN .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>caucasian healthy history current clinical finding infection disease follow nature : cerebrovascular , neurologic , cardiovascular , endocrine , pulmonary , immunologic , metabolic , hematologic , diabetes mellitus , glucose intolerance , gout nonsmoker willing abstain alcohol consumption study agree use appropriate contraception study period 3 month final study exam . history significant alcohol abuse drug abuse within 1 year prior screen visit regular use alcohol within 6 month prior screen visit ( 14 unit alcohol per week ) use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , PCP , crack ) within 1 year prior screen visit Hepatitis B C , HIV , history cancer ( exclude excise squamous basal cell carcinoma ) positive tuberculin skin test prior TB infection know history serious head injury , seizure eat disorder receive investigational drug within 30 day prior first study drug administration know hypersensitivity/allergy tacrolimus , cyclosporine , iothalamate iodine , paraaminohippuric acid , antibiotic antifungal Body mass index ( BMI ) &lt; 19 &gt; 27 clinically significant history psychiatric disease significant disability prevents understand adherence protocol renal dysfunction , serum creatinine urine microalbumin normal age genderadjusted reference range local lab clinically significant abnormal liver function test indicative impair hepatic function receive medications/herbal preparation may affect metabolism tacrolimus cyclosporine A within 1 month first study drug administration receive prescription medication within 14 day prior first study drug administration overthecounter product within 7 day prior first study drug administration , except topical product without systemic absorption current GI condition know affect GI motility and/or absorption donation plasma ( 500 mL ) within 7 day prior first study drug administration donation/ loss whole blood follow : 50 mL 499 mL within 30 day 499 mL within 56 day prior first study drug administration clinically significant surgery within 4 week prior first study drug administration administration steroid injection within 12 week prior first study drug administration administration live vaccine within 7 day prior first study drug administration travel area TB endemic within 8 week prior TB skin test perform screen visit hemoglobin &lt; 140 g/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>renal plasma flow</keyword>
	<keyword>glomerular filtration rate</keyword>
	<keyword>human</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Pharmacodynamics tacrolimus</keyword>
</DOC>